dc.contributor.author | Navarro, Miguel Octavio Perez | |
dc.contributor.author | Simionato, Ane Stefano | |
dc.contributor.author | Perez, Juan Carlos Bedoya | |
dc.contributor.author | Barazetti, Andre Riedi | |
dc.contributor.author | Emiliano, Janaina | |
dc.contributor.author | Niekawa, Erika Tyemi Goya | |
dc.contributor.author | Andreata, Matheus Felipe de Lima | |
dc.contributor.author | Modolon, Fluvio | |
dc.contributor.author | Dealis, Mickely Liuti | |
dc.contributor.author | Araujo, Eduardo Jose de Almeida | |
dc.contributor.author | Carlos, Thalita Massi | |
dc.contributor.author | Scarpelim, Odair Jose | |
dc.contributor.author | Silva, Denise Brentan da | |
dc.contributor.author | Chryssafidis, Andreas Lazaros | |
dc.contributor.author | Bruheim, Per | |
dc.contributor.author | Andrade, Galdino | |
dc.date.accessioned | 2020-02-10T08:01:56Z | |
dc.date.available | 2020-02-10T08:01:56Z | |
dc.date.created | 2019-10-29T08:43:35Z | |
dc.date.issued | 2019 | |
dc.identifier.citation | Frontiers in Microbiology. 2019, 10 . | nb_NO |
dc.identifier.issn | 1664-302X | |
dc.identifier.uri | http://hdl.handle.net/11250/2640560 | |
dc.description.abstract | The increasing emergence of multidrug-resistant (MDR) organisms in hospital infectionsis causing a global public health crisis. The development of drugs with effective antibioticaction against such agents is of the highest priority. In the present study, the actionof Fluopsin C against MDR clinical isolates was evaluated underin vitroandin vivoconditions. Fluopsin C was produced in cell suspension culture ofPseudomonasaeruginosaLV strain, purified by liquid adsorption chromatography and identified bymass spectrometric analysis. Bioactivity, bacterial resistance development risk againstclinically important pathogenic strains and toxicity in mammalian cell were initiallydetermined byin vitromodels.In vivotoxicity was evaluated inTenebrio molitorlarvae and mice. The therapeutic efficacy of intravenous Fluopsin C administration wasevaluated in a murine model ofKlebsiella pneumoniae(KPC) acute sepsis, using sixdifferent treatments. Thein vitroresults indicated MIC and MBC below 2μg/mL and lowbacterial resistance development frequency. Electron microscopy showed that FluopsinC may have altered the exopolysaccharide matrix and caused disruption of the cell wallof MDR bacteria. Best therapeutic results were achieved in mice treated with a singledose of 2 mg/kg and in mice treated with two doses of 1 mg/kg, 8 h apart. Furthermore,acute and chronic histopathological studies demonstrated absent nephrotoxicity andmoderate hepatotoxicity. The results demonstrated the efficacy of Fluopsin C againstMDR organisms inin vitroandin vivomodels, and hence it can be a novel therapeuticagent for the control of severe MDR infections | nb_NO |
dc.language.iso | eng | nb_NO |
dc.publisher | Frontiers Media | nb_NO |
dc.rights | Navngivelse 4.0 Internasjonal | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/deed.no | * |
dc.title | Fluopsin C for treating multidrug-resistant infections: In vitro activity aganist clinically important strains and in vivo efficacy against carbapenemase-producing Klebsiella pneumoniae | nb_NO |
dc.type | Journal article | nb_NO |
dc.type | Peer reviewed | nb_NO |
dc.description.version | publishedVersion | nb_NO |
dc.source.pagenumber | 12 | nb_NO |
dc.source.volume | 10 | nb_NO |
dc.source.journal | Frontiers in Microbiology | nb_NO |
dc.identifier.doi | 10.3389/fmicb.2019.02431 | |
dc.identifier.cristin | 1741491 | |
dc.description.localcode | © 2019 Navarro, Simionato, Pérez, Barazetti, Emiliano, Niekawa, Andreata, Modolon, Dealis, Araújo, Carlos, Scarpelim, da Silva, Chryssafidis, Bruheim and Andrade. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. | nb_NO |
cristin.unitcode | 194,66,15,0 | |
cristin.unitname | Institutt for bioteknologi og matvitenskap | |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.qualitycode | 2 | |